Bleeding Disorders

Bleeding Disorders

A collection of features and news articles published in ASH Clinical News related to bleeding disorders.

On location

TPO-RAs and ITP: Eltrombopag Induces High Efficacy, But Avatrombopag Offers Advantages

A pair of studies presented at the 2020 American Society of Hematology Annual Meeting analyzed the thrombopoietin receptor agonist (TPO-RA) eltrombopag in two settings:...

DDAVP Prevents Post-Intervention Bleeding Complications in Patients With Low von Willebrand Factor Levels

A recent study suggests 1-desamino-8-D-arginine vasopressin (DDAVP) prevents bleeding in patients with low von Willebrand factor (VWF) levels undergoing major and minor elective procedures....

VLX-1005 Receives Orphan Drug Designation

The FDA granted orphan drug designation to VLX-1005 as thrombosis prophylaxis in patients with heparin-induced thrombocytopenia (HIT). According to its manufacturer, Veralox Therapeutics, preclinical data...

Are Rare Cases of Immune Thrombocytopenia Linked to the COVID Vaccine?

A small number of patients have developed immune thrombocytopenia (ITP) after receiving the Pfizer/BioNTech and Moderna coronavirus vaccines. Whether the onset of the condition...
On location

New HOPE for Hemophilia B: One-Time Gene Therapy Abolishes Bleeding in Most Patients

A single dose of the gene therapy drug etranacogene dezaparvovec increased factor IX (FIX) activity levels, and eliminated the need for prophylactic FIX, in...
On location

Adding Mycophenolate to Corticosteroids Improves Response as Frontline ​Option in Immune Thrombocytopenia

In results from the randomized, controlled FLIGHT trial, patients with immune thrombocytopenia (ITP) who received mycophenolate mofetil (MMF) plus corticosteroids as first-line therapy were...

Does Blood Group Affect Risk of Bleeding Events or Bleeding Severity?

According to research published in Blood Advances, people who experience bleeding of unknown causes are 48% more likely to have blood group O, compared...

Steven Pipe: Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

Steven Pipe, MD, shares safety and efficacy data from a phase III study of etranacogene dezaparvovec gene therapy in patients with hemophilia B.

Tippi MacKenzie: In Utero Hematopoietic Cell Transplantation for Hematologic Conditions

In utero hematopoietic cell transplantation showed promise in a phase 1 clinical trial involving fetuses with alpha thalassemia major. Here, Tippi Mackenzie, MD, discusses...

What Is the Optimal Treatment of ITP?

In recent years, the number of treatment options available for patients with immune thrombocytopenia (ITP) has expanded. In addition to the classical trio of...
Advertisement

Current Issue

March 2021 Volume 7 Issue 4

This issue examines blood services across the globe, the repercussions of increased patient access to medical information, and more.

Block title